Endophthalmitis
38
4
5
16
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.3%
2 terminated out of 38 trials
88.9%
+2.4% vs benchmark
26%
10 trials in Phase 3/4
0%
0 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (38)
First-line Surgical Versus Medical Treatment: A Retrospective Study From 2014 to 2024 in Brest (BRESTE)
Nanopore Sequencing in Ophthalmology
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore
Vascular Changes Associated With Endophthalmitis.
Complex Ocular Infection, Optimization of Microbiological Diagnosis
Clinical Features and Visual Prognosis of Infectious Endophthalmitis
Evaluation and Risk Factors of Post-traumatic Endophthalmitis
Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis
Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
Endophthalmitis Post Intravitreal Injections
Study of Intraocular Concentrations (Aqueous Humor, Vitreous Humor) of Antibiotics After Local and/or Systemic Administration in Endophthalmitis
Hypochlorous Acid Disinfection Prior to Cataract Surgery
Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis
Intracameral Antibiotic Safety Study
Early Vitrectomy for Endophthalmitis After Cataract Surgery
Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin